PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 141 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $194,000 | -32.9% | 27,735 | -12.0% | 0.02% | -37.5% |
Q2 2021 | $289,000 | +112.5% | 31,530 | +134.6% | 0.02% | +166.7% |
Q3 2020 | $136,000 | -79.6% | 13,441 | -83.0% | 0.01% | -81.2% |
Q1 2020 | $667,000 | +152.7% | 79,050 | +161.9% | 0.05% | +200.0% |
Q4 2019 | $264,000 | -49.4% | 30,187 | -37.8% | 0.02% | -64.4% |
Q3 2019 | $522,000 | -79.4% | 48,506 | -25.9% | 0.04% | -75.0% |
Q1 2019 | $2,538,000 | +125.6% | 65,430 | +166.7% | 0.18% | +111.8% |
Q3 2018 | $1,125,000 | +78.0% | 24,529 | +164.3% | 0.08% | +93.2% |
Q1 2018 | $632,000 | +149.8% | 9,281 | +220.0% | 0.04% | -36.2% |
Q2 2017 | $253,000 | -57.3% | 2,900 | -85.0% | 0.07% | -26.6% |
Q4 2016 | $593,000 | -46.2% | 19,326 | +17.6% | 0.09% | -61.8% |
Q3 2016 | $1,102,000 | +15.2% | 16,429 | -49.6% | 0.25% | +119.6% |
Q1 2016 | $957,000 | -24.8% | 32,600 | +92.9% | 0.11% | +1.8% |
Q3 2015 | $1,273,000 | +356.3% | 16,900 | +604.2% | 0.11% | +254.8% |
Q2 2015 | $279,000 | – | 2,400 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 1,417,000 | $18,010,000 | 2.24% |
Palo Alto Investors LP | 1,405,680 | $17,866,000 | 0.87% |
PFM Health Sciences, LP | 2,838,376 | $36,076,000 | 0.68% |
TANG CAPITAL MANAGEMENT LLC | 349,400 | $4,441,000 | 0.60% |
Capital Impact Advisors, LLC | 127,029 | $1,615,000 | 0.59% |
Leap Investments LP | 29,100 | $370,000 | 0.50% |
Spark Investment Management LLC | 454,300 | $5,774,000 | 0.40% |
Partner Investment Management, L.P. | 27,567 | $350,000 | 0.37% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 262,945 | $3,342,000 | 0.26% |
Rock Springs Capital Management LP | 534,400 | $6,792,000 | 0.25% |